Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to use serial imaging to gain insight into the sequence of pathologic events in Alzheimer's disease, and the clinical features associated with this sequence. We measured change in amyloid deposition over time using serial (11)C Pittsburgh compound B (PIB) positron emission tomography and progression of neurodegeneration using serial structural magnetic resonance imaging. We studied 21 healthy cognitively normal subjects, 32 with amnestic mild cognitive impairment and 8 with Alzheimer's disease. Subjects were drawn from two sources--ongoing longitudinal registries at Mayo Clinic, and the Alzheimer's disease Neuroimaging Initiative (ADNI). All subjects underwent clinical assessments, MRI and PIB studies at two time points, approximately one year apart. PIB retention was quantified in global cortical to cerebellar ratio units and brain atrophy in units of cm(3) by measuring ventricular expansion. The annual change in global PIB retention did not differ by clinical group (P = 0.90), and although small (median 0.042 ratio units/year overall) was greater than zero among all subjects (P < 0.001). Ventricular expansion rates differed by clinical group (P < 0.001) and increased in the following order: cognitively normal (1.3 cm(3)/year) < amnestic mild cognitive impairment (2.5 cm(3)/year) < Alzheimer's disease (7.7 cm(3)/year). Among all subjects there was no correlation between PIB change and concurrent change on CDR-SB (r = -0.01, P = 0.97) but some evidence of a weak correlation with MMSE (r =-0.22, P = 0.09). In contrast, greater rates of ventricular expansion were clearly correlated with worsening concurrent change on CDR-SB (r = 0.42, P < 0.01) and MMSE (r =-0.52, P < 0.01). Our data are consistent with a model of typical late onset Alzheimer's disease that has two main features: (i) dissociation between the rate of amyloid deposition and the rate of neurodegeneration late in life, with amyloid deposition proceeding at a constant slow rate while neurodegeneration accelerates and (ii) clinical symptoms are coupled to neurodegeneration not amyloid deposition. Significant plaque deposition occurs prior to clinical decline. The presence of brain amyloidosis alone is not sufficient to produce cognitive decline, rather, the neurodegenerative component of Alzheimer's disease pathology is the direct substrate of cognitive impairment and the rate of cognitive decline is driven by the rate of neurodegeneration. Neurodegeneration (atrophy on MRI) both precedes and parallels cognitive decline. This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Efforts continue to be placed on the early detection of AD as changes in brain chemistry begin to occur 20 years or more prior to the onset of noticeable cognitive symptoms [137,138,139,140].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these symptoms are new to the individual affected, the brain changes that cause them are thought to begin 20 years or more before symptoms start.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319 · cited 1×
“The automated anatomic labelling (AAL) atlas (Tzourio-Mazoyer et al., 2002) was modified in-house to contain the following labelled regions of interest: right and left parietal, temporal, prefrontal, primary sensory -motor, orbito frontal, anterior cingulate, posterior cingulate/ precuneus and occipital.”
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Diagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzem, E. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0655 · Cited by 8,477
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Self-citation
Cited by
Items 701–800 of 1,000
A case of Alzheimer's disease following mild traumatic brain injury
Tateno, A., Sakayori, T., Takizawa, Y., Yamamoto, K., Minagawa, K., & Okubo, Y. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2014.09.016 · Cited by 15
Seo, E. H., Kim, S. H., Park, S. H., Kang, S., Choo, I. H., & Initiative, A. D. N. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.2.286 · Cited by 17
Krishnan, H. S., Bernard‐Gauthier, V., Placzek, M. S., Dahl, K., Narayanaswami, V., Livni, E., Chen, Z., Yang, J., Collier, T. L., Ran, C., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00936 · Cited by 15
Imaging and biomarkers for Alzheimer's disease
Allan, C. L., Sexton, C. E., Welchew, D., & Ebmeier, K. P. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.006 · Cited by 22
Models of Neurodegenerative Disease – Alzheimer’s Anatomical and Amyloid Plaque Imaging
Petiet, A., Delatour, B., & Dhenain, M. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-219-9_16 · Cited by 14
“Today, in humans, amyloid plaque imaging relies mainly on positron emission tomography and on specific ligands such as PIB (2).”
InfluentialFakorede, S., Sodiq, T. A., Ajagbe͓, A. O., Adeleke, A. J., Edafetanure-Ibeh, O. M., Awobona, T. A., & Aborode, A. T. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251377793 · Cited by 190
Longitudinal associations between β-amyloid and cortical thickness in mild cognitive impairment
Mak, E., Zhang, L., Tan, C. H., Reilhac, A., Shim, H. Y., Wen, M. O. Q., Wong, Z. X., Chong, E. J. Y., Xu, X., Stephenson, M. C., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad192 · Cited by 14
Which factors can we control the transition from mild cognitive impairment to dementia?
Ateş, M. P., & Can, F. Y. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.01.015 · Cited by 14
Miyamoto, M., Kuzuya, A., Noda, Y., Ueda, S., Asada‐Utsugi, M., Ito, S., Fukusumi, Y., Kawachi, H., Takahashi, R., & Kinoshita, A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200071 · Cited by 14
Kitaigorodsky, M., Curiel, R. E., Crocco, E., Gorman, K., González-Jiménez, C. J., Greig‐Custo, M. T., Barker, W., Duara, R., & Loewenstein, D. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.08.033 · Cited by 14
Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
Povala, G., Bellaver, B., Bastiani, M. A. D., Brum, W. S., Ferreira, P. C. L., Bieger, A., Pascoal, T. A., Benedet, A. L., Souza, D. O., Araújo, R., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00712-3 · Cited by 14
Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
Padilla, C., Montal, V., Walpert, M., Hong, Y. T., Fryer, T. D., Coles, J., Aigbirhio, F. I., Hartley, S. L., Cohen, A. D., Tudorascu, D., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12288 · Cited by 15
Ou, Y., Zhao, B. T., Fu, Y., Sheng, Z.-H., Gao, P., Tan, L., & Yu, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220649 · Cited by 15
APOE ɛ4 allele and TOMM40‐APOC1 variants jointly contribute to survival to older ages
Kulminski, A. M., Jain‐Washburn, E., Philipp, I., He, L., Loika, Y., Loiko, E., Bagley, O., Ukraintseva, S. V., Yashin, A. I., Arbeev, K. G., et al. (2022) · Aging Cell · doi:10.1111/acel.13730 · Cited by 14
Deters, J. R., Fietsam, A. C., Gander, P. E., Ponto, L. L. B., & Rudroff, T. (2023) · Brain Sciences · doi:10.3390/brainsci13040675 · Cited by 15
Su, H., Masters, C. L., Bush, A. I., Barnham, K. J., Reid, G. E., & Vella, L. J. (2023) · PROTEOMICS · doi:10.1002/pmic.202300063 · Cited by 14
Biomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 25
The concept of FDG-PET endophenotype in Alzheimer’s disease
During, E., Osorio, R. S., Elahi, F. M., Mosconi, L., & de Leon, M. J. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0633-1 · Cited by 14
Seeing with new eyes: Finding a path to early intervention trials in Alzheimer's disease
Cedarbaum, J. M., Crans, G., & Grundman, M. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0069-y · Cited by 14
Is Amnestic Mild Cognitive Impairment a Useful Concept?
Ash, E. L., & Korczyn, A. D. (2011) · Aging Health · doi:10.2217/ahe.10.90 · Cited by 15
Reinvang, I., Lundervold, A. J., Wehling, E. I., Rootwelt, H., & Espeseth, T. (2010) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617710000263 · Cited by 14
ACR–ASNR Practice Parameter for Brain PET/CT Imaging Dementia
Frey, K. A., Lodge, M. A., MELTZER, C. C., Peller, P. J., Wong, T. Z., Hess, C. P., Petrella, J. R., Sair, H. I., & Subramaniam, R. M. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001037 · Cited by 15
Amyloid burden quantification depends on PET and MR image processing methodology
Kolinger, G. D., García, D. V., Willemsen, A. T. M., Reesink, F. E., de Jong, B. M., Dierckx, R., Deyn, P. P. D., & Boellaard, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248122 · Cited by 14
Uquillas, F. D., Jacobs, H. I. L., Hanseeuw, B. J., Marshall, G. A., Properzi, M. J., Schultz, A. P., LaPoint, M. R., Johnson, K. A., Sperling, R. A., & Vannini, P. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.10.034 · Cited by 14
Beta-amyloid imaging in dementia
Chun, K. A. (2018) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2018.35.1.1 · Cited by 16
Feasibility of imaging amyloid in the brain using small-angle x-ray scattering
Choi, M., Dahal, E., & Badano, A. G. (2019) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ab501c · Cited by 15
Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI
Visser, P. J., & Knopman, D. S. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b61b5d · Cited by 14
Self-citationBerente, D. B., Zsuffa, J. A., Werber, T., Kiss, M., Drotos, A., Kamondi, A., Csukly, G., & Horvath, A. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.854368 · Cited by 13
Clinical Applications of PET Imaging in Alzheimer’s Disease
Patil, S., Ayubcha, C., Teichner, E. M., Subtirelu, R. C., Cho, J. H., Ghonim, M., Ghonim, M., Werner, T. J., Høilund‐Carlsen, P. F., Alavi, A., et al. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.09.015 · Cited by 14
Chow, T. E., Veziris, C. R., Mundada, N. S., Martinez-Arroyo, A. I., Kramer, J. H., Miller, B. L., Rosen, H. J., Gorno‐Tempini, M. L., Rankin, K. P., Seeley, W. W., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230367 · Cited by 14
Therapeutics for cognitive aging
Shineman, D. W., Salthouse, T. A., Launer, L. J., Hof, P. R., Bartzokis, G., Kleiman, R. J., Luine, V. N., Buccafusco, J. J., Small, G. W., Aisen, P. S. S., et al. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05532.x · Cited by 14
Gertje, E. C., Pluta, J. B., Das, S. R., Mancuso, L., Kliot, D., Yushkevich, P. A., & Wolk, D. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160014 · Cited by 13
Yang, W., Guan, F., Yang, L., Shou, G., Zhu, F., Xu, Y., Meng, Y., Li, M., & Dong, W. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1445479 · Cited by 13
Hojjati, S. H., Chiang, G. C.-Y., Butler, T., Chen, K., Khalafi, M., Yazdi, B. G., Foldi, N. S., Nayak, S., de Leon, M. J., Li, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70153 · Cited by 12
Autobiographical memory in Alzheimer’s disease: a systematic review
Stramba-Badiale, C., Frisone, F., Biondi, D., & Riva, G. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1546984 · Cited by 12
Alzheimer′s disease: The role for neurosurgery
Pereira, J. L., Gorgulho, A. A., Patel, V. N., Malkasian, D. R., Salles, A. D., & Downes, A. E. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.140191 · Cited by 13
Johnson, L. G., Werden, E., Shirbin, C., Bird, L., Landau, E. R., Cumming, T. B., Churilov, L. P., Bernhardt, J. A., Thijs, V., & Brodtmann, A. G. (2018) · European Stroke Journal · doi:10.1177/2396987318785845 · Cited by 13
Effect of Feru‐guard 100M on amyloid‐beta deposition in individuals with mild cognitive impairment
Matsuyama, K., Yamamoto, Y., & Sora, I. (2020) · Psychogeriatrics · doi:10.1111/psyg.12581 · Cited by 13
Thiophene-Based Ligands for Specific Assignment of Distinct Aβ Pathologies in Alzheimer's Disease
Klingstedt, T., Lantz, L., Shirani, H., Ge, J., Hanrieder, J., Vidal, R., Ghetti, B. F., & Nilsson, K. P. R. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00021 · Cited by 15
Human Brain Myelination Trajectories Across the Life Span
Sherin, J. E., & Bartzokis, G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-378638-8.00015-4 · Cited by 13
La neuroimagen molecular en las demencias degenerativas
Jiménez-Bonilla, J. F., & CARRIL, J. M. (2013) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2013.06.012 · Cited by 15
Zammit, M. D., Laymon, C. M., Tudorascu, D. L., Hartley, S. L., Piro‐Gambetti, B., Johnson, S. C., Stone, C. K., Mathis, C. A., Zaman, S. H., Klunk, W. E., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12138 · Cited by 13
Amyloid PET in neurodegenerative diseases with dementia
Camacho, V., Gómez‐Grande, A., Sopena, P., Solís, D. G., Río, M. G., Lorenzo‐Bosquet, C., Rubí, S., & Arbizu, J. (2018) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2018.04.003 · Cited by 16
Stage-independent biomarkers for Alzheimer’s disease from the living retina: an animal study
Ferreira, H. R. L., Serranho, P., Guimarães, P., Trindade, R., Martins, J., Moreira, P. I., Ambrósio, A. F., Castelo-Branco, M. S., & Bernardes, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-18113-y · Cited by 12
Repeated performance of spatial memory tasks ameliorates cognitive decline in APP/PS1 mice
Lonnemann, N., Körte, M., & Hosseini, S. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114218 · Cited by 12
Amyloid imaging in Alzheimer's disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0507-3 · Cited by 12
Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms
Lyoo, C. H., Cho, H., Choi, J. Y., Ryu, Y. H., & Lee, M. S. (2018) · Journal of Movement Disorders · doi:10.14802/jmd.17071 · Cited by 13
Carbone, M. G., Pagni, G., Tagliarini, C., Marazziti, D., & Pomara, N. (2021) · Life · doi:10.3390/life11080750 · Cited by 12
Modeling regional vulnerability to Alzheimer pathology
Royall, D. R., Palmer, R. F., Petrovitch, H., Ross, G. W., Masaki, K., & White, L. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.028 · Cited by 12
Royall, D. R., & Palmer, R. F. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131733 · Cited by 11
A novel regulator in Alzheimer's disease progression: The astrocyte-derived extracellular vesicles
Li, B., Ma, Z., & Li, Z. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101871 · Cited by 11
Pathology steered stratification network for subtype identification in Alzheimer's disease
Xu, E., Zhang, J., Li, J., Song, Q., Yang, D., Guorong Wu, A., & Chen, M. (2023) · Medical Physics · doi:10.1002/mp.16655 · Cited by 11
Sun, X., Zhu, J., Li, R., Peng, Y. F., & Gong, L. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2024.1510522 · Cited by 14
Molecular neuroimaging in degenerative dementias
Jiménez-Bonilla, J. F., & CARRIL, J. M. (2013) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2013.07.027 · Cited by 12
Proitsi, P., Lupton, M. K., Velayudhan, L., Hunter, G., Newhouse, S., Lin, K., Fogh, I., Tsolaki, M., Daniilidou, M., Pritchard, M., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.023 · Cited by 11
Alzheimer’s disease detection using artificial intelligence
Subaşı, A., Kapadnis, M. N., & Bulbul, A. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90037-9.00011-4 · Cited by 11
Risacher, S. L. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001509 · Cited by 11
Palmer, K., Musicco, M., & Caltagirone, C. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/417615 · Cited by 13
Zhai, Y., Chao, Q., Hong, L., Wang, B., Xu, R. H., Wang, N., Han, Y., He, X., Jia, X., & Wang, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145547 · Cited by 12
A correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients
Meng, Y., Li, H., Hua, R., Wang, H., Lu, J. G., Yu, X., & Zhang, C. (2015) · Scientific Reports · doi:10.1038/srep15546 · Cited by 12
Qian, L., Liu, R., Qin, R., Zhao, H., & Xu, Y. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.07.010 · Cited by 13
Avants, B., Hutchison, R. M., Mikulskis, A., Salinas, C. A., Hargreaves, R. J., Beaver, J. D., & Chiao, P. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.002 · Cited by 11
Characterization of the retinal changes of the 3×Tg-AD mouse model of Alzheimer’s disease
Ferreira, H. R. L., Martins, J., Nunes, A., Moreira, P. I., Castelo-Branco, M. S., Ambrósio, A. F., Serranho, P., & Bernardes, R. C. (2020) · Health and Technology · doi:10.1007/s12553-020-00413-w · Cited by 12
Huang, C., Hsiao, I., Lin, K., Huang, K., Fung, H., Liu, C., Chang, T., Weng, Y., Hsu, W.-C., Yen, T., et al. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.12.039 · Cited by 13
Predicting Alzheimer’s disease progression trajectory and clinical subtypes using machine learningPreprint
Satone, V. K., Kaur, R., Dadu, A., Leonard, H. L., Iwaki, H., Makarious, M. B., Sargent, L. J., Initiative, A. D. N., Daneshmand, A., Scholz, S. W., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/792432 · Cited by 14
Alzheimer's Disease and Vascular Dementia, Connecting and Differentiating Features
Hurła, M., Banaszek, N., Kozubski, W. P., & Dorszewska, J. (2024) · Current Alzheimer Research · doi:10.2174/0115672050319219240711103459 · Cited by 10
Sobczuk, J., Paczkowska, K., Andrusiów, S., Bolanowski, M., & Daroszewski, J. (2024) · Biomolecules · doi:10.3390/biom14080918 · Cited by 10
Nassrallah, W. B., Li, H. R., Irani, L., Wijesinghe, P., Hogg, P. W., Hui, L., Oh, J., Mackenzie, I. R., Hirsch‐Reinshagen, V., Hsiung, G. R., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01898-6 · Cited by 10
Advanced Neuroimaging Methods Towards Characterization of Early Stages of Alzheimer’s Disease
Sepulcre, J., & Masdeu, J. C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_31 · Cited by 11
Clarens, M. F., Crivelli, L., Calandri, I. L., Méndez, P. C., Martín, M., Russo, M. J., Campos, J., Surace, E. I., Vázquez, S., Sevlever, G. E., et al. (2020) · Applied Neuropsychology Adult · doi:10.1080/23279095.2020.1756816 · Cited by 10
Wu, Y. N., & Tang, N. (2021) · Statistics in Medicine · doi:10.1002/sim.8985 · Cited by 10
Sasaki, H., Jono, T., Fukuhara, R., Honda, K., Ishikawa, T., Boku, S., & Takebayashi, M. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03978-0 · Cited by 11
Kazemi-Harikandei, S.-Z., Shobeiri, P., Jelodar, M.-R. S., & Tavangar, S. M. (2022) · Neuroscience Informatics · doi:10.1016/j.neuri.2022.100104 · Cited by 11
Marano, G., Anesini, M. B., Milintenda, M., Acanfora, M., Calderoni, C., Bardi, F., Lisci, F. M., Brisi, C., Traversi, G., Mazza, O., et al. (2025) · Pediatric Reports · doi:10.3390/pediatric17030065 · Cited by 10
Pearson, S. D., Ollendorf, D. A., & Colby, J. A. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11711 · Cited by 11
P2–186: Resting state executive control network adaptations in amnestic mild cognitive impairment
Wu, L., Soder, R., Schoemaker, D., Carbonnell, F., Sziklas, V., Rowley, J., Mohades, S., Fonov, V., Bellec, P., Dagher, A., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.831 · Cited by 10
Nordberg, A. K., Kadir, A., Andreasen, N., Almkvist, O., Wall, A. E., Blennow, K., Långström, B., & Zetterberg, H. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-132474 · Cited by 11
Liu, S., Luo, J., Xiao, Z., Wu, W., Liang, X., Ding, S., Zhao, Q., Zhao, X., Wang, Y., & Ding, D. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1036795 · Cited by 10
PET amiloide en enfermedades neurodegenerativas que cursan con demencia
Camacho, V., Gómez‐Grande, A., Sopeña, P., García-Solís, D., Río, M. G., Lorenzo‐Bosquet, C., Rubí, S., & Arbizu, J. (2018) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2018.03.004 · Cited by 13
Burton, E. J., Mukaetova-Ladinska, E. B., Perry, R. H., Jaros, E., Barber, R., & O'Brien, J. T. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3774 · Cited by 10
Delineating the topography of amyloid-associated cortical atrophy in Down syndrome
Mak, E., Padilla, C., Annus, T., Wilson, L. R., Hong, Y. T., Fryer, T. D., Coles, J., Aigbirhio, F. I., Menon, D. K., Nestor, P. J., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.018 · Cited by 10
Tau PET probes for Alzheimer’s disease detection and their structural characterization
Chinnathambi, S., Malik, S., & Chandrashekar, M. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.006 · Cited by 15
Sex Differences in Alzheimer Disease Imaging Biomarkers in a Diverse, Community-Based Cohort
Akinci, M., Aziz, F., Palta, P., Guzman, D., Cheung, L., Teresi, J. A., Brickman, A. M., Lao, P. J., & Luchsinger, J. A. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.54524 · Cited by 9
Kannappan, B., Nijenhuis, J. T., Choi, Y. Y., Lee, J. J., Choi, K. Y., Balzekas, I., Jung, H. Y., Choe, Y., Song, M. K., Chung, J. Y., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275233 · Cited by 10
A nonlinear meccano for Alzheimer's emergence by amyloid β-mediated glutamatergic hyperactivity
Bonifazi, G., Luchena, C., Gaminde‐Blasco, A., Ortiz-Sanz, C., Capetillo‐Zarate, E., Matute, C., Alberdi, E. M., & Pittà, M. D. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106473 · Cited by 9
Biomechanical perspectives on traumatic brain injury in the elderly: a comprehensive review
Abdi, H., Sánchez‐Molina, D., Vilana, S. G., & Rahimi-Movaghar, V. (2025) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ada654 · Cited by 11
Cui, H., Yang, R., Liu, S., Fu, G., & Yang, L. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.01.012 · Cited by 9
Musicco, M., Padovani, A., Sorbi, S., Scarpini, E. A., Caffarra, P., Cappa, S. F., Clerici, F., Tabaton, M., Caltagirone, C., Bonavita, V., et al. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0825-8 · Cited by 10
The Domestic Dog as a Model for Human Brain Aging and Alzheimer’s Disease
Schütt, T., Pedersen, J. T., & Berendt, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00015-4 · Cited by 14
Placebo effect in subjects with cognitive impairment
Ito, K., & Romero, K. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.032 · Cited by 9
Sasaki, H., Jono, T., Fukuhara, R., Yuki, S., Ishikawa, T., Boku, S., & Takebayashi, M. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02949-7 · Cited by 15
Adriaanse, S. M., Dijk, K. R. A. V., Ossenkoppele, R., Reuter, M., Tolboom, N., Zwan, M. D., Yaqub, M. M., Boellaard, R., Windhorst, A. D., van der Flier, W. M., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2704-z · Cited by 11
Praet, J., Bigot, C., Orije, J. E. M. J., Naeyaert, M., Shah, D., Mai, Z., Guns, P., der Linden, A. V., & Verhoye, M. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.06.014 · Cited by 9
Machine learning for image-based classification of Alzheimer's disease
Gray, K. R. (2012) · Spiral (Imperial College London) · doi:10.25560/10522 · Cited by 28
Novau-Ferré, N., Mateu-Fabregat, J., Papagiannopoulos, C. K., Chalitsios, C. V., Panisello, L., Markozannes, G., Tsilidis, K. K., Bulló, M., & Papandreou, C. (2025) · International Journal of Epidemiology · doi:10.1093/ije/dyaf182 · Cited by 184
Light on Alzheimer’s disease: from basic insights to preclinical studies
Mi, J., Liu, C., Chen, H., Qian, Y., Zhu, J., Zhang, Y., Liang, Y., Wang, L., & Ta, D. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1363458 · Cited by 8
Yang, C.-H., Li, C., Sie, Y.-Y., Chen, L., Yuan, Y.-H., & Hou, W. (2024) · Botanical studies · doi:10.1186/s40529-024-00443-x · Cited by 8
Jiménez-Bonilla, J. F., Quirce, R., de Arcocha-Torres, M., Martínez‐Rodríguez, I., Martínez‐Amador, N., Sánchez-Salmón, A., la Fuente-Gómez, F. D., Rodríguez‐Rodríguez, E., Sánchez‐Juan, P., & Banzo, I. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001004 · Cited by 8
Fernandes, C., Macedo, I., Barbosa, F., & Teixeira, J. M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.030 · Cited by 9
Health System Change for Alzheimer’s Disease-Modifying Therapies in Canada: Beginning the Discussion
Frank, A. R., Ismail, Z., Wilson, M., Gauthier, S. G., Verret, L., Hsiung, G. R., & BORRIE, M. J. (2023) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.322 · Cited by 9
Metadata
- Authors
- Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., Weiner, M., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-31
- Volume
- 132
- Issue
- 5
- Pages
- 1355-1365
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2677798
- OpenAlex
- W2133719476
- Cited by
- 1,099
- References
- 83
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 34 · 2023: 51 · 2022: 45 · 2021: 49 · 2020: 60 · 2019: 54 · 2018: 62 · 2017: 46 · 2016: 56 · 2015: 69 · 2014: 73 · 2013: 94 · 2012: 116
- FWCI
- 71.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Mayo Foundation for Medical Education and Research (AG16574)
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institute on Aging (R01AG11378, P01AG010491, P50‐AG16574, U01AG06786, AG 024904, R01AG027342, U01AG006786, R01AG011378, P30AG019610, U19AG010483, P50AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, amyloid deposition, neurodegeneration, brain atrophy, ventriculomegaly, Pittsburgh compound B PET, serial imaging, amyloid plaques, cognitive decline, Alzheimer's Disease Neuroimaging Initiative, brain atrophy rate
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Atrophy, Brain, Carbon Radioisotopes, Cognition Disorders, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Thiazoles, Time Factors, Case-Control Studies, Amyloid beta-Peptides, Statistics, Nonparametric, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.